Technical Analysis for APRE - Aprea Therapeutics, Inc.

Grade Last Price % Change Price Change
F 4.46 -4.09% -0.19
APRE closed down 4.09 percent on Monday, April 19, 2021, on 33 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical APRE trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -4.09%
Bullish Engulfing Bullish -4.09%
Stochastic Buy Signal Bullish -4.09%
New 52 Week Low Weakness -4.09%
Outside Day Range Expansion -4.09%
Wide Bands Range Expansion -4.09%
Lower Bollinger Band Touch Weakness -4.09%
Older End-of-Day Signals for APRE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 13 hours ago
60 Minute Opening Range Breakdown about 15 hours ago
Down 5% about 16 hours ago
Down 3% about 17 hours ago
Rose Above Previous Day's High about 17 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aprea Therapeutics, Inc. Description

Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes Myelodysplastic Syndromes Lactams P53 Tumor Suppressor Genes Tumor Suppressor

Is APRE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 41.115
52 Week Low 4.2001
Average Volume 1,191,389
200-Day Moving Average 18.43
50-Day Moving Average 5.74
20-Day Moving Average 4.90
10-Day Moving Average 4.70
Average True Range 0.40
ADX 20.27
+DI 22.66
-DI 27.38
Chandelier Exit (Long, 3 ATRs ) 5.05
Chandelier Exit (Short, 3 ATRs ) 5.39
Upper Bollinger Band 5.59
Lower Bollinger Band 4.20
Percent B (%b) 0.19
BandWidth 28.43
MACD Line -0.38
MACD Signal Line -0.38
MACD Histogram 0.0027
Fundamentals Value
Market Cap 94.49 Million
Num Shares 21.2 Million
EPS -22.79
Price-to-Earnings (P/E) Ratio -0.20
Price-to-Sales 0.00
Price-to-Book 5.71
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.90
Resistance 3 (R3) 4.93 4.81 4.82
Resistance 2 (R2) 4.81 4.70 4.80 4.80
Resistance 1 (R1) 4.64 4.63 4.58 4.61 4.77
Pivot Point 4.52 4.52 4.50 4.51 4.52
Support 1 (S1) 4.35 4.41 4.29 4.32 4.15
Support 2 (S2) 4.23 4.34 4.22 4.12
Support 3 (S3) 4.06 4.23 4.10
Support 4 (S4) 4.03